⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6643626 | 0.71 | NPC1 (0.50) | — | |
| SCHEMBL19417413 | 0.71 | — | — | |
| SCHEMBL268792 | 0.71 | — | — | |
| Ammonia Solution, Strong SCHEMBL27345029 | 0.69 | — | — | |
| SCHEMBL15070886 | 0.69 | — | — | |
| SCHEMBL15229739 | 0.67 | — | — | |
| SCHEMBL24669723 | 0.67 | — | — | |
| SCHEMBL19623761 | 0.67 | — | — | |
| SCHEMBL3328791 | 0.67 | — | — | |
| SCHEMBL15108916 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224168-A1 | ARYL SULFONE AND SULFANONE DERIVATIVES AS OREXIN RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-30 | — | — | WO | disclosed |
| CN-119968366-A | Oxadiazole derivatives, methods of preparation and use thereof in the treatment of inflammatory diseases | 西特瑞治疗有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-04 | — | — | US | disclosed |
| WO-2022155419-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2020023657-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |